Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANDROID 25 vs ISOVUE-300
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.
Iodinated radiocontrast agent that attenuates X-rays, providing enhanced visualization of vascular structures and body cavities during imaging procedures.
Hypogonadism in males (primary and secondary),Delayed puberty in males,Metastatic breast cancer in women (as palliative therapy)
Intravascular administration for radiography (e.g., angiography, urography),Intrathecal administration for myelography,Intracavitary administration for arthrography, hysterosalpingography, etc.
Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.
Intravenous: 50-150 m L (up to 300 mg iodine/kg) as a bolus or infusion; intra-arterial: 5-40 m L depending on procedure; intrathecal: 8-15 m L. Maximum total iodine dose: 300 mg iodine/kg.
Terminal elimination half-life: 10–100 minutes (testosterone); clinical context: rapid clearance necessitates frequent dosing or use of esters for sustained effect
Terminal elimination half-life in patients with normal renal function is approximately 2 hours. In patients with moderate to severe renal impairment (creatinine clearance <30 m L/min), the half-life can be prolonged up to 20–40 hours, requiring dose adjustment.
Primarily hepatic via reduction and oxidation; metabolites include androsterone and etiocholanolone; excreted in urine.
Not metabolized; excreted unchanged by glomerular filtration.
Renal: 90% (as glucuronide and sulfate conjugates, 5–10% unchanged); fecal/biliary: 10%
Primarily renal (glomerular filtration), with >95% of administered dose excreted unchanged in urine within 24 hours. Less than 1% is excreted via bile/fecal route.
97–99% (sex hormone-binding globulin and albumin)
Iopamidol (active ingredient) is minimally protein bound (<5%), primarily to albumin.
0.3–0.6 L/kg; indicates distribution into lean muscle and sex organs
Approximately 0.20–0.30 L/kg, indicating distribution primarily within extracellular fluid space; low tissue binding.
Oral: <5% (methyltestosterone: ~20–25% due to 17α-alkylation); IM: 100%
Not applicable for oral route as it is used only intravascularly or intrathecally; bioavailability is 100% for IV injection and near 100% for intra-arterial and intrathecal administration.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing dose or increasing interval; monitor for fluid retention and hypertension.
GFR <30 m L/min: Use with caution; consider lower dose and ensure adequate hydration. GFR <15 m L/min: Avoid use unless essential; post-procedure hemodialysis may be considered. No specific dose reduction formula; clinical judgment advised.
Contraindicated in Child-Pugh class B or C cirrhosis. For mild hepatic impairment (Child-Pugh A), start with lower dose (e.g., 12.5 mg every 2 weeks) and titrate based on response and liver function.
No specific Child-Pugh based dose adjustments; use cautiously in severe hepatic impairment due to altered pharmacokinetics.
Not recommended for use in pediatric patients (safety and efficacy not established). For male adolescents with hypogonadism, individualize: start at 12.5 mg every 2 weeks and adjust based on testosterone levels and growth.
Weight-based: 1-2 m L/kg (300 mg iodine/m L) intravenously; maximum total dose 300 mg iodine/kg. Adjust for body habitus and procedure.
Start with lower initial dose (e.g., 12.5 mg every 2 weeks); monitor prostate-specific antigen (PSA) and hematocrit frequently. Avoid in patients with prostate cancer or untreated sleep apnea.
Elderly patients may have reduced renal function; assess GFR and adjust dose accordingly. Ensure adequate hydration before and after procedure. Monitor for nephrotoxicity and hypersensitivity.
WARNING: Androgens are contraindicated in pregnancy due to masculinization of female fetus. Hepatotoxicity, including peliosis hepatis and hepatic neoplasms, has been reported with prolonged use.
No FDA boxed warning.
Use with caution in patients with hepatic, renal, or cardiovascular disease; may cause gynecomastia, edema, hypercalcemia, and polycythemia; monitor liver function, lipid profile, and hematocrit periodically; may accelerate bone maturation in children; risk of prostate hypertrophy and urethral obstruction.
Risk of serious hypersensitivity reactions (including anaphylaxis),Acute kidney injury in patients with pre-existing renal impairment or other risk factors,Thyroid dysfunction (especially in neonates) due to iodine load,Pregnancy and lactation considerations
Known or suspected prostate cancer; male breast cancer; pregnancy; lactation; hypersensitivity to methyltestosterone; severe hepatic impairment.
Known hypersensitivity to iopamidol or any components of the formulation,History of severe adverse reaction to iodinated contrast agents
Take with food containing fat (e.g., avocado, nuts, olive oil) to enhance absorption. Avoid grapefruit juice as it may increase testosterone levels via CYP3A4 inhibition. Limit alcohol due to potential liver effects.
No specific food interactions. However, patients are typically advised to avoid solid food for a few hours before the procedure (e.g., 4-6 hours NPO prior to injection) to reduce the risk of aspiration if emesis occurs. Also, ensure adequate hydration: recommend clear liquids (water, juice) unless contraindicated (e.g., pre-procedure fasting for other reasons).
Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure occurs before 12 weeks gestation. Second and third trimesters: Continued risk of female pseudohermaphroditism, and potential for masculinization of female external genitalia. Androgens can cross the placenta and may also cause skeletal abnormalities and growth retardation. Pregnancy category X.
Iodinated contrast agents like Isovue-300 (iopamidol) cross the placenta. First trimester: Avoid unless essential; theoretical risk of fetal hypothyroidism from free iodide. Second/third trimester: Risk of transient neonatal hypothyroidism if high doses used; fetal goiter reported. No teratogenic effects at clinical doses in animal studies.
Methyltestosterone is excreted into breast milk; M/P ratio not established. May cause virilization in female infants and premature sexual development in male infants. Androgens can suppress lactation. Use during breastfeeding is contraindicated.
Iopamidol is excreted into breast milk in small amounts (<1% of maternal dose). M/P ratio not established. Discontinue breastfeeding for 12-24 hours after administration, or pump and discard. Use only if clearly needed.
Android 25 is contraindicated in pregnancy, so no dosing adjustments are applicable. If used inadvertently, discontinue immediately. No pharmacokinetic data to guide dose changes; avoid use entirely.
No specific dose adjustments for pregnancy; use lowest effective dose. Increased plasma volume may slightly dilute contrast, but no dose change recommended. Avoid in patients with impaired renal function or hyperthyroidism.
Android 25 (testosterone undecanoate) requires absorption via lymphatic system; administer with fat-containing meal. Monitor serum testosterone levels 3-5 hours post-dose. Avoid in patients with breast cancer or known or suspected prostate cancer. Risk of polycythemia; check hematocrit before and during therapy.
ISOVUE-300 (iopamidol) is a nonionic, low-osmolality iodinated contrast medium used for intravascular and intrathecal administration. Key pearls: 1) Pre-hydrate patients with normal saline to reduce risk of contrast-induced nephropathy, especially in those with e GFR <30 m L/min/1.73m². 2) Screen for prior allergic-like reactions; consider premedication with corticosteroids (e.g., prednisone 50 mg PO q12h for 3 doses prior) and antihistamines (diphenhydramine 50 mg IV/PO 1 hour before) for history of moderate or severe reactions. 3) Avoid intrathecal use if there is suspicion of elevated intracranial pressure or CSF obstruction. 4) Metformin should be held for 48 hours post-procedure and only resumed after renal function recheck. 5) Have emergency equipment (oxygen, epinephrine, IV access) readily available for treatment of anaphylactoid reactions.
Take capsules with meals, especially those containing fat, to improve absorption.,Do not chew or crush capsules; swallow whole.,Report signs of deep vein thrombosis (leg swelling, pain) or pulmonary embolism (sudden dyspnea, chest pain).,Women of reproductive potential should avoid pregnancy; use effective contraception.,Keep out of reach of children; testosterone can cause serious harm if accidentally ingested.,Regular blood tests (testosterone, hematocrit, PSA, lipid profile) are required.
This contrast agent may cause a warm sensation or metallic taste during injection; these sensations are temporary.,Notify the technologist immediately if you experience itching, hives, difficulty breathing, or swelling of the face or throat.,You should drink plenty of fluids (water) before and after the procedure to help clear the contrast from your kidneys unless otherwise instructed.,If you take metformin for diabetes, you may need to stop it for 48 hours after the procedure; your doctor will advise when to restart.,Inform your healthcare provider about any allergies (especially to iodine or contrast media), kidney problems, asthma, or if you are pregnant or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANDROID 25 vs ISOVUE-300, answered by our medical review team.
ANDROID 25 is a Androgen that works by Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.. ISOVUE-300 is a Contrast Media that works by Iodinated radiocontrast agent that attenuates X-rays, providing enhanced visualization of vascular structures and body cavities during imaging procedures.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANDROID 25 and ISOVUE-300 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANDROID 25 is: Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.. The standard adult dose of ISOVUE-300 is: Intravenous: 50-150 m L (up to 300 mg iodine/kg) as a bolus or infusion; intra-arterial: 5-40 m L depending on procedure; intrathecal: 8-15 m L. Maximum total iodine dose: 300 mg iodine/kg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANDROID 25 and ISOVUE-300 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANDROID 25 is classified as Category C. Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure oc. ISOVUE-300 is classified as Category C. Iodinated contrast agents like Isovue-300 (iopamidol) cross the placenta. First trimester: Avoid unless essential; theoretical risk of fetal hypothyroidism from free iodide. Second. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.